Lectins as a promising therapeutic agent for breast cancer: A review
Breast Disease · 2024
DOI: 10.3233/bd-230047 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Breast Disease, 2024. Verfasst von Keerti Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Breast Neoplasms, Lectins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Efficient treatment of cancer has been a subject of research by scientists for many years. Current treatments for cancer, such as radiotherapy, chemotherapy and surgery have been used in traditional combination therapy, but they have major setbacks like non-specificity, non-responsiveness in certain cancer types towards treatment, tumor recurrence, etc. Epidemiological data has shown that breast cancer accounts for 14% of cancer cases occurring in Indian women. In recent years, scientists have started to focus on the use of natural compounds like lectins obtained from various sources to counter the side effects of traditional therapy. Lectins like Sambucus nigra Agglutinin, Maackia amurensis lectin, Okra lectins, Haliclona caerulea lectin, Sclerotium rolfsii lectin, etc., have been discovered to have both diagnostic and therapeutic potential for breast cancer patients. Lectins have been found to have inhibitory effects on various cancer cell activities such as neo-angiogenesis, causing cell cycle arrest at the G1 phase, and inducing apoptosis. The major idea behind the use of lectins in cancer diagnostics and therapeutics is their capability to bind to glycosylated proteins that are expressed on the cell surface. This review focuses on an exploration of the roles of post-translational modification in cancer cells, especially glycosylation, and the potential of lectins in cancer diagnosis and therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.
Zitieren
APA
Singh, K., Agrawal, L., Gupta, R., Singh, D., Kathpalia, M., & Kaur, N. (2024). Lectins as a promising therapeutic agent for breast cancer: A review. Breast Disease. https://doi.org/10.3233/bd-230047
Vancouver
Singh K, Agrawal L, Gupta R, Singh D, Kathpalia M, Kaur N. Lectins as a promising therapeutic agent for breast cancer: A review. Breast Disease. 2024. doi:10.3233/bd-230047
BibTeX
@article{Singh2024,
author = {Singh, Keerti and Agrawal, Lokita and Gupta, Rhea and Singh, Divyam and Kathpalia, Meghavi and Kaur, Navkiran},
title = {Lectins as a promising therapeutic agent for breast cancer: A review},
journal = {Breast Disease},
year = {2024},
doi = {10.3233/bd-230047}
}
EUVIMED